Penn Pharma has secured multiple contracts with companies in Europe, the U.S., and Japan less than two months after officially opening the doors of its new high potency manufacturing facility.
The facility was designed to meet the growing market need for contained manufacturing processes. According to a company statement, "Successfully securing multiple global contracts in such a short space of time has verified Penn’s vision and investment strategy that led to the design and build of this new state-of-the-art facility." Penn announced its plans to build the new facility in 2012 and the first batch of coated tablets were produced in May of this year.
Richard Yarwood, Penn Pharma’s chief executive officer, commented, “Our vision is to become the preferred partner for the supply of oral doses containing potent molecules for both investigational and commercial use, and this facility will help us to achieve this."